Drug:
Reaction: DERMATITIS ATOPIC
20250101 - 20251231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 25108107 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 402 | 25108108 |
US |
18 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 403 | 25108110 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 404 | 25108119 |
US |
2 | 2 |
Dermatitis atopic, Dry skin, Rash pruritic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 405 | 25108128 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 406 | 25108131 |
US |
19 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 407 | 25108139 |
US |
44 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 408 | 25108141 |
US |
27 | 2 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 409 | 25108142 |
US |
48 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 410 | 25108159 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, OSELTAMIVIR, OSELTAMIVIR PHOSPHATE, PIMECROLIMUS, CETIRIZINE HYDROCHLORIDE, |
||||
| 411 | 25108165 |
US |
43 | 2 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 412 | 25108166 |
US |
2 | |
Dermatitis atopic, Rash, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 413 | 25108184 |
US |
16 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 414 | 25108196 |
US |
4 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 415 | 25108209 |
US |
47 | 2 |
Gastrointestinal disorder, Dermatitis atopic, Gastritis, Diarrhoea, |
||||
DUPILUMAB, |
||||
| 416 | 25108212 |
US |
84 | 1 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 417 | 25108214 |
US |
63 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 418 | 25108215 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 419 | 25108224 |
US |
17 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 420 | 25108266 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 421 | 25108276 |
US |
43 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 422 | 25108324 |
US |
29 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 423 | 25108333 |
US |
57 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 424 | 25108358 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 425 | 25108360 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 426 | 25108512 |
US |
57 | 1 |
Neck surgery, Dermatitis atopic, Pain, Rash papular, Skin discharge, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 427 | 25108664 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 428 | 25108683 |
US |
2 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 429 | 25108706 |
US |
21 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 430 | 25108793 |
US |
17 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 431 | 25108907 |
US |
71 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 432 | 25108908 |
US |
41 | 2 |
Back pain, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 433 | 25108913 |
US |
57 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 434 | 25108916 |
US |
29 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 435 | 25108945 |
US |
17 | 2 |
Dermatitis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 436 | 25108957 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 437 | 25108958 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 438 | 25108959 |
US |
54 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 439 | 25108978 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 440 | 25109002 |
US |
52 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 441 | 25109013 |
US |
20 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 442 | 25109049 |
US |
37 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 443 | 25109101 |
US |
6 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 444 | 25109106 |
US |
19 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, METHYLPHENIDATE HYDROCHLORIDE, |
||||
| 445 | 25102443 |
US |
82 | 1 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 446 | 25102470 |
FR |
21 | 1 |
Pneumothorax, Dermatitis atopic, COVID-19, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 447 | 25102526 |
US |
41 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 448 | 25102528 |
US |
54 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 449 | 25102531 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 450 | 25102591 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 451 | 25102623 |
US |
66 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 452 | 25102679 |
US |
24 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 453 | 25102681 |
US |
44 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 454 | 25102792 |
US |
80 | 1 |
Eye pruritus, Lacrimation increased, Eye pain, Head and neck cancer, Contusion, Cardiac ventricular thrombosis, Monoparesis, Dermatitis atopic, Pruritus, Ocular rosacea, Eczema, |
||||
APIXABAN, DUPILUMAB, DUPILUMAB, |
||||
| 455 | 25103584 |
US |
45 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 456 | 25103703 |
US |
26 | 2 |
Drug ineffective, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 457 | 25103709 |
US |
32 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 458 | 25104115 |
US |
50 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 459 | 25106443 |
US |
||
Psoriatic arthropathy, Rheumatoid arthritis, Uveitis, Dermatitis atopic, Hidradenitis, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 460 | 25097305 |
US |
43 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 461 | 25097313 |
US |
60 | 2 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 462 | 25097370 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 463 | 25097438 |
US |
12 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 464 | 25097440 |
US |
71 | 1 |
Dermatitis atopic, Sensitivity to weather change, |
||||
DUPILUMAB, |
||||
| 465 | 25097448 |
US |
68 | 2 |
Fall, Swelling, Haemorrhage, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 466 | 25097492 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 467 | 25097505 |
US |
22 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 468 | 25097569 |
US |
50 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 469 | 25097768 |
US |
51 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 470 | 25097770 |
US |
3 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 471 | 25097779 |
US |
59 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 472 | 25097907 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 473 | 25098002 |
US |
20 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 474 | 25098016 |
US |
2 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 475 | 25098017 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 476 | 25098167 |
US |
33 | 1 |
Pruritus, Swelling, Dermatitis atopic, Sensitive skin, |
||||
TRALOKINUMAB-LDRM, |
||||
| 477 | 25098171 |
US |
48 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 478 | 25098190 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 479 | 25098347 |
US |
54 | 2 |
Dry skin, Skin exfoliation, Dermatitis atopic, Pruritus, Dry eye, Eye pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 480 | 25098540 |
US |
53 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 481 | 25098739 |
US |
27 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 482 | 25098831 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 483 | 25098905 |
US |
63 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 484 | 25098954 |
US |
35 | 1 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 485 | 25099027 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 486 | 25099104 |
US |
4 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 487 | 25099110 |
US |
67 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, IVERMECTIN, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, VORTIOXETINE, BUPROPION HYDROCHLORIDE, BUPROPION, PIMECROLIMUS, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, FINASTERIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, TADALAFIL, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, FAMOTIDINE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, LORAZEPAM, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, |
||||
| 488 | 25099281 |
US |
31 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 489 | 25099282 |
US |
25 | 2 |
Dermatitis atopic, Dermatitis, Pruritus, |
||||
DUPILUMAB, |
||||
| 490 | 25099286 |
US |
27 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, VINBLASTINE SULFATE, PREDNISONE, MINOCYCLINE HYDROCHLORIDE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, OSELTAMIVIR PHOSPHATE, OSELTAMIVIR ACID, OSELTAMIVIR, |
||||
| 491 | 25099416 |
US |
7 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 492 | 25099425 |
US |
82 | 2 |
Diarrhoea, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 493 | 25099463 |
US |
10 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 494 | 25099620 |
US |
19 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 495 | 25099622 |
US |
31 | 2 |
Eating disorder, Stress, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 496 | 25099629 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 497 | 25099638 |
US |
36 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 498 | 25099720 |
US |
61 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 499 | 25099726 |
US |
70 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 500 | 25099760 |
US |
48 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28